Skip to Main Content

Phase I CRT

Objectives:

  • To develop new and improved cancer therapeutics.
  • To maintain a portfolio of novel cancer therapeutics to service our cancer patient community
  • To assist in the development, understanding, characterization, and approval of new drug therapies
  • Strategically cultivate and nurture sponsored research activities

Research Meetings: Thursday @ 1:45 - 3:30PM

Phase I Team Leader

  • Amy and Joseph Perella Professor of Medicine (Medical Oncology); Chief, Experimental Therapeutics; Associate Cancer Center Director, Experimental Therapeutics

    Pat LoRusso brings more than 25 years of expertise in medical oncology, drug development, and early phase clinical trials. Prior to her Yale appointment, she served in numerous leadership roles at Wayne State University’s Barbara Karmanos Cancer Institute, most recently as director of the Phase I Clinical Trials Program and of the Eisenberg Center for Experimental Therapeutics.

Members

  • Associate Professor of Medicine (Medical Oncology); Co-Director, Colorectal Program in the Center for Gastrointestinal Cancers; Medical Oncology Section Lead for National Accreditation Program for Rectal Cancer, Internal Medicine

  • Associate Professor of Internal Medicine (Medical Oncology); Director, Prostate Cancer Research; Lecture Coordinator in Hematology/Oncology, Yale Affiliated Hospital Program

    Dr. Joseph Kim is a board-certified medical oncologist and a Director of the Prostate Cancer Research Program for Prostate and Urological Cancers DART of Yale Cancer Center.  He is a recipient of the Cancer Clinical Investigator Team Leadership Award from the National Cancer Institute (NCI) and a recipient of other awards from Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO). Dr. Kim has led several peer-reviewed, NCI-sponsored, investigator-initiated clinical trials in prostate cancer, bladder cancer, and other solid tumors as a study chair. Dr. Joseph Kim serves as an author/editor of the genitourinary (GU) cancers chapter of  ASCO-SEP, an educational textbook for medical oncologists, and a co-editor of the GU cancers section of a peer-reviewed journal, Current Oncology Report, and ad hoc reviewer of multiple oncology journals. He has been invited as a speaker for numerous international and national academic conferences including GU Cancers Symposium, ASCO Annual Meeting, CTEP/ NCI meeting, ASCO Direct highlights, International Genitourinary Cancer Conference, and many others. His passion lies in delivering compassionate, patient-centered, and evidence-based care for patients with genitourinary cancer including prostate cancer, bladder, and other urinary tract cancer, testicular cancer, and penile cancer.  He is also passionate about developing and executing hypothesis-driven clinical trials of novel therapies in GU cancers and other solid tumors.
  • Assistant Professor

    So Yeon Kim, MD, is an Assistant Professor of Medicine (Medical Oncology) at Yale School of Medicine. Dr. Kim completed her undergraduate studies at Princeton University and received her medical degree from Albert Einstein College of Medicine. She completed her internal medicine residency at Tufts Medical Center and completed her hematology oncology fellowship at Montefiore Medical Center. Dr. Kim's clinical practice is focused primarily on caring for patients with thoracic malignancies. In 2022, she received the ASCO Merit Award based on her research on MET exon14 skipping mutations in non-small cell lung cancer. Her ongoing research interests include targeted treatment and immunotherapy approaches in lung cancer.
  • Amy and Joseph Perella Professor of Medicine (Medical Oncology); Chief, Experimental Therapeutics; Associate Cancer Center Director, Experimental Therapeutics

    Pat LoRusso brings more than 25 years of expertise in medical oncology, drug development, and early phase clinical trials. Prior to her Yale appointment, she served in numerous leadership roles at Wayne State University’s Barbara Karmanos Cancer Institute, most recently as director of the Phase I Clinical Trials Program and of the Eisenberg Center for Experimental Therapeutics.